Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis | ||
Avicenna Journal of Phytomedicine | ||
دوره 12، شماره 6، بهمن و اسفند 2022، صفحه 576-588 اصل مقاله (777.98 K) | ||
نوع مقاله: Review Article | ||
شناسه دیجیتال (DOI): 10.22038/ajp.2022.20049 | ||
نویسندگان | ||
Elham Emami1؛ Saeid Heidari-Soureshjani* 2؛ Catherine MT Sherwin3 | ||
1Department of Pediatric Nephrology, Emam Hossein Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran | ||
2Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran | ||
3Department of Pediatric Clinical Pharmacology, Department of Pharmacology & Toxicology, Wright State University Boonshoft School of Medicine, Dayton Children's Hospital, One Children's Plaza, Dayton, Ohio, USA | ||
چکیده | ||
Objective: This study was designed to determine the association curcumin has on pro-inflammatory biomarkers in patients with chronic kidney disease (CKD (and in those receiving hemodialysis (HD). Materials and Methods: This meta-analysis was undertaken following PRISMA guidelines. An extensive systematic review was undertaken until 10/11/2021 using PubMed, Web of Science (ISI), and Scopus databases. The standardized mean difference (SMD) and 95% confidence intervals (CI) were used to estimate the overall effect size of curcumin on serum high-sensitivity C-reactive protein (hs-CRP), and pro-inflammatory cytokines including interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) in patients with CKD and those receiving HD. Results: Overall, ten randomized controlled trials (RCTs) comprising 523 patients were incorporated into the systematic review and meta-analysis. The results showed that when compared with control groups, there was no significant effect observed linking curcumin and IL-6 (SMD = 0.24%, 95% CI = -0.14 to 0.62, p = 0.221), TNF-α (SMD = 0.11%, 95% CI = -0.19 to 0.40, p = 0.480) or hs-CRP (SMD = -0.17%, 95% CI = -0.36 to 0.03, p = 0.093). The analysis determined no publication bias related to the influence of curcumin on IL-6, TNF-α or acute phase reactant, hs-CRP. The Egger’s and Begg’s test results were not statistically significant (p˃0.20). Conclusion: In patients with CKD and those receiving HD, the use of curcumin supplementation has no statistically significant effect on the anti-inflammatory biomarkers reviewed in this study. | ||
کلیدواژهها | ||
Chronic kidney disease؛ Hemodialysis؛ Curcumin؛ Inflammation | ||
مراجع | ||
Alvarenga L, Leal VO, Borges NA, Aguiar ASd, Faxén-Irving G, Stenvinkel P, Lindholm B, Mafra D. 2018. Curcumin - A promising nutritional strategy for chronic kidney disease patients. J Funct Foods, 40: 715-721. Alvarenga L, Salarolli R, Cardozo L, Santos RS, de Brito JS, Kemp JA, Reis D, de Paiva BR, Stenvinkel P, Lindholm B, Fouque D, Mafra D. 2020. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Clin Nutr, 39: 3594-3600. Ammirati AL. 2020. Chronic Kidney Disease. Rev Assoc Med Bras (1992), 66Suppl 1: s03-s09. Bagherniya M, Soleimani D, Rouhani MH, Askari G, Sathyapalan T, Sahebkar A. 2021. The use of curcumin for the treatment of renal disorders: a systematic review of randomized controlled trials. Adv Exp Med Biol, 1291: 327-343. Bartaula B, Subedi M, Kumar MM, Shrestha M, Bichha N, Mudbhari B. 2019. Spectrum of complications in chronic kidney disease patients undergoing maintenance hemodialysis: An experience of a tertiary care center in Nepal. Saudi J Kidney Dis Transpl, 30: 208-214. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. 2008. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif, 26: 291-299. Chan WH, Wu HY, Chang WH. 2006. Dosage effects of curcumin on cell death types in a human osteoblast cell line. Food Chem Toxicol, 44: 1362-1371. GBD Chronic Kidney Disease Collaboration. 2020. Global, regional, and national burden of chronic kidney disease, 1990- 2017: a systematic analysis for the global burden of disease study 2017. Lancet, 395: 709-733. Corsonello A, Freiberger E, Lattanzio F. 2020. The screening for chronic kidney disease among older people across Europe (SCOPE) project: findings from crosssectional analysis. BMC Geriatr, 20: 316- 316. Crewe C, An YA, Scherer PE. 2017. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest, 127: 74-82. Ferguson JJA, Abbott KA, Garg ML. 2021. Anti-inflammatory effects of oral supplementation with curcumin: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev, 79: 1043-1066. Gorabi AM, Razi B, Aslani S, Abbasifard M, Imani D, Sathyapalan T, Sahebkar A. 2021. Effect of curcumin on proinflammatory cytokines: A metaanalysis of randomized controlled trials. Cytokine, 143: 155541. Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 15: 195-218. Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A, Narimanyan M, Hovhannisyan A. 2018. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med, 18: 7. Hasan M, Sutradhar I, Gupta RD, Sarker M. 2018. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrol, 19: 291-291. Jiménez-Osorio AS, García-Niño WR, González-Reyes S, Álvarez-Mejía AE, Guerra-León S, Salazar-Segovia J, Falcón I, de Oca-Solano HM, Madero M, Pedraza-Chaverri J. 2016. The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr, 26: 237-244. Kabodan MH, Kooshki A, Rad M, Tabarraie Y, Sharifipour F. 2018. Investigating the effect of curcumin supplement consumption on systematic inflammation in hemodialysis patients. Int J Life Sci Pharma Res, 8: 39-47. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G. 2011. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo- Anti-inflammatory response to curcumin hemodialysis AJP, Vol. 12, No. 6, Nov-Dec 2022 587 controlled study. Scand J Urol Nephrol, 45: 365-370. Kotha RR, Luthria DL. 2019. Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules, 24: 2930. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. 2017. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol, 174: 1325-1348. Marton LT, Barbalho SM, Sloan KP, Sloan LA, Goulart RA, Araújo AC, Bechara MD. 2022. Curcumin, autoimmune and inflammatory diseases: going beyond conventional therapy – a systematic review. Crit Rev Food Sci Nutr, 62: 2140- 2157. Memarzia A, Khazdair MR, Behrouz S, Gholamnezhad Z, Jafarnezhad M, Saadat S, Boskabady MH. 2021. Experimental and clinical reports on anti-inflammatory, antioxidant, and immunomodulatory effects of Curcuma longa and curcumin, an updated and comprehensive review. Biofactors, 47: 311-350. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, Mambet C, Anton G, Tanase C. 2018. Inflammationrelated mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res, 2018: 2180373. Miller PD. 2014. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep, 3: 542-542. Mohammad pour A, Dastani M, Salari R, Radbin S, Mehri S, Ghorbani M, Karimani A, Salari M. 2019. Curcumin effects on myeloperoxidase, interleukin-18 and matrix metalloproteinase-9 inflammatory biomarkers in patients with unstable angina: A randomized clinical trial. Avicenna J Phytomed, 9: 428-435. Moreillon JJ, Bowden RG, Deike E, Griggs J, Wilson R, Shelmadine B, Cooke M, Beaujean A. 2013. The use of an antiinflammatory supplement in patients with chronic kidney disease. J Complement Integr Med, 10: 1-10. Moreno Velásquez I, Tribaldos Causadias M, Valdés R, Gómez B, Motta J, Cuero C, Herrera-Ballesteros V. 2019. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study. BMJ Open, 9: e027229. Najafi H, Changizi Ashtiyani S, Sayedzadeh SA, Mohamadi yarijani Z, Fakhri S. 2015. Therapeutic effects of curcumin on the functional disturbances and oxidative stress induced by renal ischemia/reperfusion in rats. Avicenna J Phytomed, 5: 576-586. Pakfetrat M, Akmali M, Malekmakan L, Dabaghimanesh M, Khorsand M. 2015. Role of turmeric in oxidative modulation in end-stage renal disease patients. Hemodial Int, 19: 124-131. Pakfetrat M, Basiri F, Malekmakan L, Roozbeh J. 2014. Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. J Nephrol, 27: 203-207. Pretto CR, Winkelmann ER, Hildebrandt LM, Barbosa DA, Colet CF, Stumm EMF. 2020. Quality of life of chronic kidney patients on hemodialysis and related factors. Rev Lat Am Enfermagem, 28: e3327 Rahban M, Habibi-Rezaei M, Mazaheri M, Saso L, Moosavi-Movahedi AA. 2020. Anti-viral potential and modulation of Nrf2 by curcumin: pharmacological implications. Antioxidants, 9: 1228. Rodrigues HCN, Martins TFP, Santana N, Braga CC, Silva MAC, Cunha LCD, Sugizaki CSA, Freitas A, Costa NA, Peixoto M. 2021. Antioxidant and antiinflammatory response to curcumin supplementation in hemodialysis patients: A randomized, double-blind, placebocontrolled clinical trial. Clin Nutr ESPEN, 44: 136-142. Salarolli RT, Alvarenga L, Cardozo L, Teixeira KTR, de SGML, Lima JD, Rodrigues SD, Nakao LS, Fouque D, Mafra D. 2021. Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study. Int Urol Nephrol, 53: 1231-1238. Samadian F, Dalili N, Poor-Reza Gholi F, Fattah M, Malih N, Nafar M, Firoozan A, Ahmadpoor P, Samavat S, Ziaie S. 2017. Evaluation of curcumin's effect on inflammation in hemodialysis patients. Clin Nutr ESPEN, 22: 19-23. Shafabakhsh R, Asemi Z, Reiner Z, Soleimani A, Aghadavod E, Bahmani F. 2020. The effects of nano-curcumin on metabolic Emami et al. AJP, Vol. 12, No. 6, Nov-Dec 2022 588 status in patients with diabetes on hemodialysis, a randomized, double blind, placebo-controlled trial. Iran J Kidney Dis, 14: 290-299. Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, Sestito S, Rapposelli S, Neffe-Skocińska K, Zielińska D, Salehi B, Setzer WN, Dosoky NS, Taheri Y, El Beyrouthy M, Martorell M, Ostrander EA, Suleria HAR, Cho WC, Maroyi A, Martins N. 2020. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Front Pharmacol, 11: 01021. Shelmadine BD, Bowden RG, Moreillon JJ, Cooke MB, Yang P, Deike E, Griggs JO, Wilson RL. 2017. A pilot study to examine the effects of an anti-inflammatory supplement on eicosanoid derivatives in patients with chronic kidney disease. J Altern Complement Med, 23: 632-638. Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR, Preuss HG. 2020. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules, 25: 1397. Subeesh VK, Abraham R, Satya Sai MV, Koonisetty KS. 2020. Evaluation of prescribing practices and drug-related problems in chronic kidney disease patients: A cross-sectional study. Perspect Clin Res, 11: 70-74. Tinti F, Lai S, Noce A, Rotondi S, Marrone G, Mazzaferro S, Di Daniele N, Mitterhofer AP. 2021. Chronic kidney disease as a systemic inflammatory syndrome: update on mechanisms involved and potential treatment. Life, 11: 419. Vafadar-Afshar G, Rasmi Y, Yaghmaei P, Khadem-Ansari MH, Makhdoomi K, Rasouli J. 2021. The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: A randomized controlled trial. Hemodial Int, 25: 232-239. Vafadar Afshar G, Rasmi Y, Yaghmaei P, Khadem-Ansari MH, Makhdomii K, Rasooli J. 2020. The effects of nanocurcumin supplementation on serum Level of hs-CRP, adhesion molecules, and lipid profiles in hemodialysis patients, a randomized controlled clinical trial. Iran J Kidney Dis, 14: 52-61. Vanaie A, Shahidi S, Iraj B, Siadat ZD, Kabirzade M, Shakiba F, Mohammadi M, Parvizian H. 2019. Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy. J Res Med Sci, 24: 77. Welz AN, Emberger-Klein A, Menrad K. 2018. Why people use herbal medicine: insights from a focus-group study in Germany. BMC Complement Altern Med, 18: 92. White CM, Pasupuleti V, Roman YM, Li Y, Hernandez AV. 2019. Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res, 146: 104280. Whittaker CF, Miklich MA, Patel RS, Fink JC. 2018. Medication safety principles and practice in CKD. Clin J Am Soc Nephrol, 13: 1738-1746. Xu G, Gu Y, Yan N, Li Y, Sun L, Li B. 2021. Curcumin functions as an antiinflammatory and antioxidant agent on arsenic-induced hepatic and kidney injury by inhibiting MAPKs/NF-κB and activating Nrf2 pathways. Environ Toxicol, 36: 2161-2173. Yang H, Xu W, Zhou Z, Liu J, Li X, Chen L, Weng J, Yu Z. 2015. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp Clin Endocrinol Diabetes, 123: 360-367. Yuan H, Ma Q, Ye L, Piao G. 2016. The traditional medicine and modern medicine from natural products. Molecules, 21: 559. | ||
آمار تعداد مشاهده مقاله: 24,318 تعداد دریافت فایل اصل مقاله: 10,027 |